OBJECTIVES: Cervical cancer (CC) remains the leading cause of cancer death among Colombian women. Human papillomavirus (HPV) 16 and 18 infection is associated with CC while HPV 6 and 11 are related to genital warts (GW). Currently are available 2 vaccines against HPV. Bivalent protects against carcinogenic genotypes and tetravalent also protects against genotypes GW associated. We present the cost-effectiveness evaluation of the introduction of two vaccination strategies in Colombian women taking into account the current screening program.  METHODS: We designed a Markov model, which simulates the natural history of CC and GW in a cohort of women. The occurrence parameters were extracted and validated with a literature review and national databases. The costs were estimated from costing of standard cases. We estimated the impact of the introduction of bivalent and tetravalent HPV vaccines. We compared the different strategies in a competitive scenario and built the ICERs. A sensitivity analysis was carried out. RESULTS: In a cohort of 430,859 women followed for the entire life without vaccination or screening programs 15,284 CC cases and 18,275 GW episodes may occur. The CC would cause 4733 deaths. The screening program would prevent 3015 CC deaths. Either vaccination alternatives prevents 1958 CC deaths additional to screening program, and they are cost-effective when compared against non-vaccination.  In a competitive analysis, vaccination with bivalent+screnning is dominated while vaccination with tetravalent+screening is cost-effective (ICER per DALY averted US $ 1239). The results are sensitive to changes in the parameters of progression of neoplastic disease.  CONCLUSIONS: Economic evaluation of HPV vaccines in Colombian scenario shows that bivalent vaccination is a dominated strategy, while tetravalent vaccination is cost-effective at a willingness to pay less than 1 GDP per capita per DALY averted. The relative advantage of tetravalent is due to avoided of costs and DALYs due to GW.